May 2021 tender notification

Medicines

Tender Closed

PHARMAC is pleased to provide the latest tender results.

Tender results

PHARMAC has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020.

Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:

  • For new listings, by 4pm on 12 June 2021 or the 5th of the month prior to listing, whichever is earlier
  • For price changes, by 4pm on the 12th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information. 

More information about this process and NOPC forms can be found on our website.

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link)  and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).

Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).

PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2020/21 Tender – Principal Supply Status applies until 30 June 2024

CORRECTION to February 2021 tender notification

PHARMAC incorrectly notified a Principal Supply Status award in the Community and Hospital in February 2021 for betamethasone dipropionate with calcipotriol as ‘tube’ when this should have been a ‘bottle’. Correction in strikethrough and bold below:

1.  Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Principal Supply brand
(Supplier)

Date of subsidy change

Principal Supply date

Betamethasone dipropionate with calcipotriol

Gel 500 mcg with calcipotriol 50 mcg per g, 60 g tube bottle

$52.24

$39.35

Daivobet (LEO Pharma)

1 July 2021

1 December 2021

2.  Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

Chemical name

Presentation;
Pack size and type

Current pack price

New pack price

Principal Supply brand (Supplier)

DV Limit

Listing date

Principal Supply Status date

Betamethasone dipropionate with calcipotriol

Gel 500 mcg with calcipotriol               50 mcg per g, 60 g tube bottle

$52.24

$39.35

Daivobet (LEO Pharma)

5%

1 July 2021

1 December 2021

 

2020/21 Tender – Principal Supply Status applies until 30 June 2024

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Principal Supply brand
(Supplier)

Date of subsidy change

Principal Supply date

Modafinil1

Tab 100 mg; 60 tablet blister pack

$64.00

$29.13

Modavigil
(Teva)

1 October 2021

1 March 2022

1This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(ii) of the 2020/21 Invitation To Tender.

See table 5 below for changes to the Pharmaceutical Schedule in relation to azacitidine.

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Principal Supply brand (Supplier)

Date of subsidy change

Principal Supply date

Brand
(Supplier
affected by delisting)

Flucloxacillin cap

 

cap 250 mg; 250 capsule bottle

$16.83

$15.79

Flucloxacillin-AFT
(AFT)

1 December 2021

1 May 2022

Staphlex
(Mylan)

Flucloxacillin cap

cap 500 mg; 500 capsule bottle

$56.61

$52.99

Flucloxacillin-AFT
(AFT)

1 December 2021

1 May 2022

Staphlex
(Mylan)

Melatonin2

Tab modified-release 2 mg; 30 tablet blister pack

$28.22

$11.50

Vigisom
(Aspen Pharma)

1 November 2021

1 April 2022

Circadin
(Aspen Pharma)

Travoprost

Eye drops 0.004%; 2.5 ml OP

$19.50

$9.75

Travatan (pharmacode 2550091)(Novartis)

1 July 2021

1 December 2021

Travatan (pharmacode 2144581)
(Novartis)

Mylan (pharmacode 2602296)
(Mylan)

Travopt (pharmacode 2523035)
(Mylan)

2 Brand switch fee of $4.50 is payable for this product from 1 April 2022 to 30 June 2022

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Principal Supply brand
(Supplier)

DV
Limit

Listing date

Principal Supply Status date

Azacitidine3

Inj 100 mg vial, 1 vial pack

$139.00

$75.06

Azacitidine Dr Reddy’s
(Dr Reddy’s)

5%

1 July 2021

1 December 2021

Linezolid

Inj 2 mg per ml; 300 ml bottle

$18.50 (per 1)

$155.00 (per 10)

Linezolid Kabi
(Fresenius Kabi)

5%

1 July 2021

1 December 2021

 

Modafinil4

Tab 100 mg; 60 tablet blister pack

$64.00

$29.13

Modavigil
(Teva)

5%

1 October 2021

1 March 2022

 

3 The price and subsidy of azacitidine (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 July 2021. The subsidy of azacitidine (Baxter) inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will also be amended from $1.53 per 1 mg to $0.83 per 1 mg from 1 July 2021.

4 This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b)(ii) of the 2020/21 Invitation To Tender.

 

6. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current pack price

New pack price

Principal Supply brand (Supplier)

DV Limit

Listing date

Principal Supply Status date

Brand
(Supplier)
affected by delisting

Flucloxacillin cap

 

cap 250 mg; 250 capsule bottle

$16.83

$15.79

Flucloxacillin-AFT
(AFT)

5%

1 December 2021

1 May 2022

Staphlex

(Mylan)

Flucloxacillin cap

cap 500 mg; 500 capsule bottle

$56.61

$52.99

Flucloxacillin-AFT
(AFT)

5%

1 December 2021

1 May 2022

Staphlex

(Mylan)

Melatonin

Tab modified-release 2 mg; 30 tablet blister pack

$28.22

$11.50

Vigisom
(Aspen Pharma)

5%

1 November 2021

1 April 2022

Circadin

(Aspen Pharma)

Milrinone

Inj 1 mg per ml, 10 ml ampoule; 10 ampoule pack

$99.00

$71.00

Milrinone-Baxter
(Baxter)

5%

1 July 2021

1 December 2021

Primacor

(Sanofi-Aventis)

Travoprost

Eye drops 0.004%; 2.5 ml

$19.50

$9.75

Travatan (pharmacode 2550091)
(Novartis)

5%

1 July 2021

1 December 2021

Travopt
(Mylan)

Tender declines - Products where no tender is to be awarded for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

  • the 2020/21 Invitation to Tender, dated 2 November 2020
  • the 2019/20 Invitation to Tender, dated 1 November 2019

2020/21 Invitation to Tender

Chemical name

Line item

Alprostadil

Inj 500 mcg per ml, 1 ml

Azacitidine (widened access)

Inj 100 mg

Azithromycin

Grans for oral liq 200 mg per 5 ml

Cabergoline

Tab 0.5 mg (2 pack)

Cabergoline

Tab 0.5 mg (8 pack)

Calcium Gluconate

Inj 10%, 10 ml

Cisplatin

Inj 1 mg per ml, 50 ml

Desferrioxamine mesilate

Inj 500 mg

Diclofenac sodium

Inj 25 mg per ml, 3 ml

Diclofenac sodium

Suppos 100 mg

Diclofenac sodium

Suppos 12.5 mg

Diclofenac sodium

Suppos 25 mg

Diclofenac sodium

Suppos 50 mg

Diclofenac sodium

Tab 50 mg dispersible

Disopyramide phosphate

Cap 100 mg

Efavirenz

Tab 200 mg

Efavirenz

Tab 50 mg

Efavirenz

Tab 600 mg

Efavirenz

Oral liq 30 mg per ml

Ferrous sulphate with ascorbic acid

tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500

Glyceryl trinitrate

Inj 1 mg per mL, 10 mL

Hydrocortisone

Oint  1% (pack size greater than 100 g)

Hydrocortisone

Oint 1% (pack size 100 g or less)

Idarubicin Hydrochloride

Inj 10 mg

Idarubicin Hydrochloride

Inj 5 mg

Lidocaine [Lignocaine] Hydrochloride

Gel 2%

Lopinavir with Ritonavir

Oral liq 80 mg with ritonavir 20 mg per ml

Netupitant with Palonosetron

Cap netupitant 300 mg with palonosetron 500 mcg

Noradrenaline

Inj 0.06 mg per ml, 100 ml bag

Noradrenaline

Inj 0.12 mg per ml, 50 ml syringe

Noradrenaline

Inj 0.16 mg per ml, 100 ml bag

Noradrenaline

Inj 0.16 mg per ml, 50 ml vial

Noradrenaline

Inj 1 mg per ml, 100 ml bag

Pamidronate disodium

Inj 3 mg per ml, 10 ml

Pamidronate disodium

Inj 6 mg per ml, 10 ml

Pamidronate disodium

Inj 9 mg per ml, 10 ml

Pancreatic enzyme

Cap 175 mg

Povidone Iodine

Antiseptic soln 10% (pack size 15 ml or less)

Povidone Iodine

Antiseptic soln 10% (pack size greater than 100 ml)

Povidone Iodine

Skin preparation, povidone iodine 10% with 30% alcohol (pack size 100 ml or less)

Povidone Iodine

Skin preparation, povidone iodine 10% with 30% alcohol (pack size greater than 100 ml)

Povidone Iodine

Skin preparation, povidone iodine 10% with 70% alcohol (pack size 100 ml or less)

Povidone Iodine

Skin preparation, povidone iodine 10% with 70% alcohol (pack size greater than 100 ml)

Ziprasidone

Cap 80 mg

 

2019/20 Invitation to Tender

Insulin pen needles

29 g x 12.7 mm

Insulin pen needles

31 g x 5 mm

Insulin pen needles

31 g x 6 mm

Insulin pen needles

31 g x 8 mm

Insulin pen needles

32 g x 4 mm

Insulin syringes, disposable with attached needle:

0.3 ml with 29 g x 12.7 mm needle

Insulin syringes, disposable with attached needle:

0.3 ml with 31 g x 8 mm needle

Insulin syringes, disposable with attached needle:

0.3 ml with 29 g x 6 mm needle

Insulin syringes, disposable with attached needle:

0.5 ml with 29 g x 12.7 mm needle

Insulin syringes, disposable with attached needle:

0.5 ml with 31 g x 8 mm needle

Insulin syringes, disposable with attached needle:

0.5 ml with 29 g x 6 mm needle

Insulin syringes, disposable with attached needle:

1 ml with 29 g x 12.7 mm needle

Insulin syringes, disposable with attached needle:

1 ml with 31 g x 8 mm needle

Insulin syringes, disposable with attached needle:

1 ml with 29 g x 6 mm needle

Mupirocin

Intra-nasal ointment 2%

Mupirocin

Topical ointment 2%

Phenylephrine hydrochloride

Inj 10 mg per ml, 1 ml vial

Zinc

cream (pack size 50 g or less)

Zinc

cream (pack size greater than 50 g)

Zinc

ointment (pack size 50 g or less)

Zinc

ointment (pack size greater than 50 g)

Zinc

paste (pack size 50 g or less)

For products included in the 2018/19, 2019/20 and 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.